The Peptide Apelin Made Mouse Hearts Pump Stronger Without Causing Harmful Enlargement
Apelin, a naturally occurring peptide, boosted cardiac output by 76% over 14 days in mice while reducing cardiac workload — all without causing the harmful heart enlargement seen with other heart-strengthening drugs.
Quick Facts
What This Study Found
The endogenous peptide apelin powerfully improved heart function in mice without causing harmful heart enlargement. Acute injection increased ventricular elastance by 76% (from 3.7 to 6.5 mmHg/RVU, P=0.018) and nearly doubled preload recruitable stroke work (from 27.4 to 51.8, P=0.059). It also reduced left ventricular end diastolic area (P=0.006) and modestly increased heart rate (P=0.03).
Chronic 14-day infusion increased cardiac output by 76% (from 0.142 to 0.25 L/min, P=0.001) and circumferential shortening velocity (P=0.049). Critically, post-mortem analysis showed no cardiac hypertrophy — heart weights and cell sizes were identical between apelin and control groups. The apelin receptor (APJ) was found throughout the adult mouse heart and was expressed in embryonic myocardium as early as day 13.5.
Key Numbers
Acute: 300 μg/kg IP · LVEDA decreased (0.122→0.104 cm², P=0.006) · HR increased (537→559 bpm, P=0.03) · Ventricular elastance +76% (P=0.018) · PRSW +89% (P=0.059) · Chronic: 2 mg/kg/day for 14 days · Cardiac output +76% (P=0.001) · VCF increased (P=0.049) · No hypertrophy (P=0.5 heart weight, P=0.9 cell density)
How They Did This
Researchers used three complementary cardiac imaging techniques in C57BL/6 mice: ECG/respiration-gated MRI, conductance catheter pressure-volume measurements, and 15 MHz echocardiography. Acute effects were measured after single IP injection (300 μg/kg). Chronic effects were assessed after 14 days of continuous infusion (2 mg/kg/day via implanted pump). Post-mortem histology and immunohistochemistry evaluated hypertrophy and receptor localization.
Why This Research Matters
Heart failure is a leading cause of death, and most drugs that strengthen the heart's pumping (positive inotropes) eventually cause harmful heart enlargement or increase the risk of dangerous heart rhythms. Apelin achieved the rare combination of improving contractility and reducing cardiac workload without any hypertrophy — exactly the hemodynamic profile clinicians want for heart failure therapy. This positions apelin as a fundamentally different kind of heart-strengthening agent.
The Bigger Picture
Heart failure treatment has long searched for a drug that strengthens the heart without causing it to enlarge or become prone to dangerous rhythms — most positive inotropes increase mortality long-term. Apelin's ability to improve contractility while reducing preload and afterload without hypertrophy represents an ideal hemodynamic profile. This 2005 study was foundational in establishing apelin as a cardiovascular peptide of therapeutic interest, and the apelin/APJ system has since become a major research target in cardiology.
What This Study Doesn't Tell Us
This is a mouse study in healthy animals, not in heart failure models. The beneficial hemodynamic profile may differ in diseased hearts. Sample sizes appear small (standard deviations suggest small groups), and some P-values approach but don't reach significance (PRSW P=0.059). The 14-day chronic study is relatively short for assessing long-term cardiac remodeling.
Questions This Raises
- ?Does apelin maintain its beneficial hemodynamic profile in actual heart failure models, where cardiac physiology is fundamentally altered?
- ?Could apelin or APJ receptor agonists be developed into practical heart failure drugs with sustained effects?
- ?What is the significance of APJ expression as early as embryonic day 13.5 — does apelin play a role in heart development?
Trust & Context
- Key Stat:
- +76% cardiac output 14-day chronic apelin infusion in mice, with zero cardiac hypertrophy (P=0.001 for output, P=0.5 for heart weight)
- Evidence Grade:
- This is a well-designed animal study using multiple complementary cardiac measurement techniques, published in Cardiovascular Research (a respected journal). However, it used healthy mice rather than heart failure models, and sample sizes appear small.
- Study Age:
- Published in 2005, this was a landmark early study establishing apelin's cardiovascular effects. Two decades of subsequent research have confirmed and extended these findings, with apelin pathway drug development ongoing.
- Original Title:
- The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo.
- Published In:
- Cardiovascular research, 65(1), 73-82 (2005)
- Authors:
- Ashley, Euan A, Powers, Jennifer, Chen, Mary, Kundu, Ramendra, Finsterbach, Tom, Caffarelli, Anthony, Deng, Alicia, Eichhorn, Jens, Mahajan, Raina, Agrawal, Rani, Greve, Joan, Robbins, Robert, Patterson, Andrew J, Bernstein, Daniel, Quertermous, Thomas
- Database ID:
- RPEP-01008
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is apelin and where does it come from in the body?
Apelin is a small peptide hormone produced naturally throughout the body, including in the heart, brain, and blood vessels. It acts on the APJ receptor to regulate heart function, blood pressure, and fluid balance. It was discovered in 1998 and has since become one of the most studied cardiovascular peptides.
Why is it significant that apelin didn't cause heart enlargement?
Most drugs that make the heart pump harder (positive inotropes like dobutamine or milrinone) eventually cause the heart muscle to thicken and enlarge — a condition called hypertrophy that actually worsens heart failure over time. Apelin strengthened contractions and boosted output without any enlargement, making it fundamentally different from existing heart-strengthening drugs.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-01008APA
Ashley, Euan A; Powers, Jennifer; Chen, Mary; Kundu, Ramendra; Finsterbach, Tom; Caffarelli, Anthony; Deng, Alicia; Eichhorn, Jens; Mahajan, Raina; Agrawal, Rani; Greve, Joan; Robbins, Robert; Patterson, Andrew J; Bernstein, Daniel; Quertermous, Thomas. (2005). The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo.. Cardiovascular research, 65(1), 73-82.
MLA
Ashley, Euan A, et al. "The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo.." Cardiovascular research, 2005.
RethinkPeptides
RethinkPeptides Research Database. "The endogenous peptide apelin potently improves cardiac cont..." RPEP-01008. Retrieved from https://rethinkpeptides.com/research/ashley-2005-the-endogenous-peptide-apelin
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.